Targeted de-repression of neuronal Nrf2 inhibits α-synuclein accumulation

Cell Death Dis. 2021 Feb 26;12(2):218. doi: 10.1038/s41419-021-03507-z.

Abstract

Many neurodegenerative diseases are associated with neuronal misfolded protein accumulation, indicating a need for proteostasis-promoting strategies. Here we show that de-repressing the transcription factor Nrf2, epigenetically shut-off in early neuronal development, can prevent protein aggregate accumulation. Using a paradigm of α-synuclein accumulation and clearance, we find that the classical electrophilic Nrf2 activator tBHQ promotes endogenous Nrf2-dependent α-synuclein clearance in astrocytes, but not cortical neurons, which mount no Nrf2-dependent transcriptional response. Moreover, due to neuronal Nrf2 shut-off and consequent weak antioxidant defences, electrophilic tBHQ actually induces oxidative neurotoxicity, via Nrf2-independent Jun induction. However, we find that epigenetic de-repression of neuronal Nrf2 enables them to respond to Nrf2 activators to drive α-synuclein clearance. Moreover, activation of neuronal Nrf2 expression using gRNA-targeted dCas9-based transcriptional activation complexes is sufficient to trigger Nrf2-dependent α-synuclein clearance. Thus, targeting reversal of the developmental shut-off of Nrf2 in forebrain neurons may alter neurodegenerative disease trajectory by boosting proteostasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / metabolism
  • Astrocytes / pathology
  • CRISPR-Associated Protein 9 / genetics
  • CRISPR-Associated Protein 9 / metabolism
  • CRISPR-Cas Systems*
  • Cell Death / drug effects
  • Cells, Cultured
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Coculture Techniques
  • Epigenetic Repression
  • Female
  • Gene Targeting*
  • Hydroquinones / pharmacology*
  • Lewy Body Disease / genetics
  • Lewy Body Disease / metabolism
  • Lewy Body Disease / pathology
  • Lewy Body Disease / therapy*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • NF-E2-Related Factor 2 / agonists*
  • NF-E2-Related Factor 2 / genetics
  • NF-E2-Related Factor 2 / metabolism
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neurons / pathology
  • Neuroprotective Agents / pharmacology*
  • Prosencephalon / drug effects*
  • Prosencephalon / metabolism
  • Prosencephalon / pathology
  • Proteostasis / drug effects
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism*

Substances

  • Hydroquinones
  • NF-E2-Related Factor 2
  • Neuroprotective Agents
  • Nfe2l2 protein, mouse
  • SNCA protein, human
  • alpha-Synuclein
  • 2-tert-butylhydroquinone
  • CRISPR-Associated Protein 9